Cytonics Corporation’s Post

Ready to join us on our mission to eradicate #osteoarthritis? 🖇 invest.cytonics.com The StartEngine community has come out in full force. 💰 Here are some campaign statistics: ✅ Over $2,600,000 raised from over 1,100 investors ✅ 25% of these have NEVER placed an equity crowdfund investment... we are their first foray into the world of #equitycrowdfunding ✅ 60% are returning Cytonics Corporation shareholders... ❤️ their loyalty is testament to our ability to hit the milestones on our mission! ✅ Over 3,500 prospective investors are following our campaign 🤝 Empowering A Healthier Future Investing in Cytonics is more than a financial decision; it’s a partnership in a transformative health movement. Your contribution is crucial in advancing CYT-108 through clinical trials, pushing it closer to FDA approval and into the hands of those who need it most. Your investment signifies joining a community dedicated to eradicating osteoarthritis and improving health globally. Become a shareholder here: invest.cytonics.com #biotechnology #investing #crowdfunding #arthritis #drugdevelopment

🕛ONE Week Left to Invest in Our Breakthrough Biotech 🖇 invest.cytonics.com Since 2006, Cytonics has been leading the charge in developing groundbreaking therapies for osteoarthritis. With the steadfast support of our investors, we have successfully raised over $25 million, pushing our innovative CYT-108 therapy into Phase 1 human clinical trials. We invite you to join us on our mission to rid the world of osteoarthritis, once and for all. With 1 week remaining (campaign ends August 25 at 11:59pm PST / August 26th at 2:59am EST), seize the chance to join over 6,000 dedicated shareholders committed to eradicating osteoarthritis, once and for all. This is more than an investment in a breakthrough biotech; it's an investment in the improvement of human health and well-being for generations to come. #biotechnology #drugdevelopment #clinicaltrials #arthritis #regenerativemedicine #investing #crowdfunding

🕛ONE Week Left to Invest in Our Breakthrough Biotech 🖇 invest.cytonics.com Since 2006, Cytonics Corporation has been leading the charge in developing groundbreaking therapies for osteoarthritis. With the steadfast support of our investors, we have successfully raised over $25 million, pushing our innovative CYT-108 therapy into Phase 1 human clinical trials. We invite you to join us on our mission to rid the world of osteoarthritis, once and for all. With 1 week remaining (campaign ends August 25 at 11:59pm PST / August 26th at 2:59am EST), seize the chance to join over 6,000 dedicated shareholders committed to eradicating osteoarthritis, once and for all. This is more than an investment in a breakthrough biotech; it's an investment in the improvement of human health and well-being for generations to come. #biotechnology #drugdevelopment #clinicaltrials #arthritis #regenerativemedicine #investing #crowdfunding

Curie.Bio, a biotech accelerator and investor, said Wednesday it raised $380 million to support its portfolio companies beyond the seed stage, helping advance their drugs into the clinic with Series A rounds. The Cambridge, MA-based firm has 20 therapeutics startups in its portfolio thus far, and one has so far publicly disclosed a Series A. That company, Forward Therapeutics, unveiled a $50 million Series A last November with three oral small molecules in just 18 months. Others are coming up behind it: Astoria Biologica, Decrypt Biomedicine and Differentiated Therapeutics. The firm said it invests in single-asset and platform biotechs, but each drug "must have blockbuster potential," meaning at least $1 billion in peak sales. Christoph Lengaeur, Curie chief scientific officer and co-founder, told me last November the firm sifts through about 1,000 applications a year. "There are some that are good, but you're not really excited about it or it's not for us, or it needs more work, and then there's a lot of shit out there, too, but that's OK. At least, that's how we perceive it. That doesn't mean that's the way it is. We can be wrong." #biotech #vc #venturecapital #accelerator #drugdevelopment #biotechstartups

Karna D Shinde, an early-stage angel investor, has made an undisclosed investment in Navaux, a life science company located in Arkansas, USA. Navaux is a specialist in the early detection of cancer and the monitoring of treatment, employing a state-of-the-art blood test known as ACTIVH. Karna D Shinde’s #investment in Navaux extends beyond pecuniary assistance. He contributes invaluable insights and a hands-on approach to the company’s expansion. To share your startup information write us on - startup@viestories.com Read more - https://lnkd.in/gTGgp2Kz #funding #stratup #latestupdate #healthtech #Navaux #fundingalert #news

Collaboration in the non-profit sector is key to actually solving problems (whatever the societal issue). I love what the Reeve Foundation is doing with this new venture fund with others in SCI research …… #collaboration #venturefund

🦾 Our Army Of 5,000 Shareholders Is Growing By The Day... Discover how our army of loyal Cytonics Corporation shareholders is propelling us towards revolutionizing regenerative medicine! 🖇 invest.cytonics.com 💸 Fundraising Triumphs: A Collective Achievement To date, we have raised over $25M in pursuit of developing the first and only therapy for osteoarthritis. This monumental effort boasts: ➡️ A $4M investment from Synthes (a medical device company acquired by Johnson and Johnson for $19B), alongside ➡️ $10M raised through equity crowdfunding, with ➡️ Over 100 orthopedic surgeons who utilize our APIC therapy for osteoarthritis and understand the significance of our drug development program. Our Cytonics family has expanded to over 5,000 shareholders who have played a pivotal role in our success through repeat investment, an outpouring of encouragement, and spreading the word. Every investor, regardless of the size of their committment, is a part of our family and treated as such. The current round has welcomed over 1,100 new shareholders, many of whom are placing their first equity crowdfunding investment (292 to be exact)! 🔍 A Closer Look Into Our Campaign The unwavering loyalty and commitment of our shareholders is a testament to the deep trust and shared goals that bind us. This round alone has raised over $2.7M from more than 1,100 investors, 60% of whom are returning shareholders. This remarkable rate of recurring investment is not just a metric of success but a beacon of the belief in our mission, confidence in management, and the impact of our research. ❤️ In Gratitude Your continued support and belief in Cytonics are more than just a financial decision; you are the driving force behind our relentless pursuit of improving human well-being. It's a shared journey towards creating long-term value and making a significant impact on the lives of those affected by osteoarthritis. #biotechnology #arthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine

#fundingalert 💼Company: GlycanAge 💰Funding: €3.9 Million  ⚡Round: Seed 👥Investors: Kadmos Capital Ltd, LAUNCHub Ventures. GlycanAge was founded by Gordan Lauc. The strategic move from the longevity industry to the larger #diagnostics market will be made possible in large part by the recently raised money. With the help of this funding, GlycanAge will be able to create a well-defined regulatory plan and product #pipeline in order to develop predictive biomarkers unique to individual diseases. GlycanAge, their #contemporary way of life has #fundamentally altered how we live and can have positive or negative effects on their #health. Nikolina Lauc Lyuben Belov John Gebeily Read more - https://lnkd.in/gph8QMRm To share your startup story write us on - contact@startuprise.co.uk #glycanAge #funding #eustartup

🦾 Our Army Of 5,000 Shareholders Is Growing By The Day... Discover how our army of loyal Cytonics Corporation shareholders is propelling us towards revolutionizing regenerative medicine! 🖇 invest.cytonics.com 💸 Fundraising Triumphs: A Collective Achievement To date, we have raised over $25M in pursuit of developing the first and only therapy for osteoarthritis. This monumental effort boasts: ➡️ A $4M investment from Synthes (a medical device company acquired by Johnson and Johnson for $19B), alongside ➡️ $10M raised through equity crowdfunding, with ➡️ Over 100 orthopedic surgeons who utilize our APIC therapy for osteoarthritis and understand the significance of our drug development program. Our Cytonics family has expanded to over 5,000 shareholders who have played a pivotal role in our success through repeat investment, an outpouring of encouragement, and spreading the word. Every investor, regardless of the size of their committment, is a part of our family and treated as such. The current round has welcomed over 1,100 new shareholders, many of whom are placing their first equity crowdfunding investment (292 to be exact)! 🔍 A Closer Look Into Our Campaign The unwavering loyalty and commitment of our shareholders is a testament to the deep trust and shared goals that bind us. This round alone has raised over $2.7M from more than 1,100 investors, 60% of whom are returning shareholders. This remarkable rate of recurring investment is not just a metric of success but a beacon of the belief in our mission, confidence in management, and the impact of our research. ❤️ In Gratitude Your continued support and belief in Cytonics are more than just a financial decision; you are the driving force behind our relentless pursuit of improving human well-being. It's a shared journey towards creating long-term value and making a significant impact on the lives of those affected by osteoarthritis. #biotechnology #arthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine

#fundingalert 💼Company: Scorpion Therapeutics 💰Funding: $150 Million ⚡Round: Series C 👥Investors: Frazier Life Sciences , Lightspeed Venture Partners, Willett Advisors and leading #healthcare institutional investors, Omega Funds, Vida Ventures, Atlas Venture, Abingworth, Fidelity Management & Research Company, Boxer Capital, EcoR1 Capital, LLC, Surveyor Capital (a Citadel company), Invus, Wellington Management, Nextech Invest Ltd. (on behalf of one or more funds managed by it), OrbiMed, Logos Capital, Woodline Partners LP, and Casdin Capital, LLC. Scorpion is a pioneering clinical-stage oncology company redefining the frontier of precision medicine to deliver optimized and transformational therapies for larger populations of patients with cancer. Adam Friedman, MD, PhD Albert Cha Read more - https://lnkd.in/gHkJzyni To share your startup story write us on - contact@startuprise.io #Scorpion #fundraising #